NEW YORK — AxoGen Inc. shares surged more than 11% on Tuesday, April 28, 2026, climbing to $43.98 in morning trading after the peripheral nerve repair company delivered a strong first-quarter revenue beat, posted adjusted profitability and raised its full-year 2026 guidance while announcing it had become debt-free following a successful public offering.
The regenerative medicine company reported first-quarter revenue of $61.5 million, a robust 26.6% increase from $48.6 million in the same period last year and well above analyst expectations around $57.85–$58.9 million. Gross margin expanded to 75.2% from 71.9% a year earlier, reflecting improved product mix and operational efficiencies.
